Evommune, Inc. (EVMN) intrinsic value & 10-year financials
Evommune, Inc. (EVMN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 3 fiscal years revenue grew 85.7% a year to $13.0M, with an average return on invested capital of -2665.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.17
- Market cap
- $31.7M
- Revenue (FY2025)
- $13.0M
- Revenue growth (3-yr CAGR)
- 85.7%
- ROIC (10-yr avg)
- -2665.2%
- Free cash flow (FY2025)
- -$76.7M
EVMN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $13.0M | -$68.9M | -$11.22 | -$76.7M | -623.6% | -5374.3% |
| FY2024 | $7.0M | -$66.8M | -$11.32 | -$58.3M | -1000.2% | 43.8% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Evommune, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Evommune, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.0% ROIC.
Evommune, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Evommune, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-372.68 per share.